Table 4 Treatment outcome after the grouping

Stage IIB and IIIB

 Overall recurrence

13/49 (26.5%)

17/34 (50%)

0.029

 In-field recurrence

6/49 (12.2%)

12/34 (35.3%)

0.012

 Out-field recurrence

9/49 (18.4%)

16/34 (47.1%)

0.005

Stage IIIC1

 Total recurrence

11/54 (20.4%)

18/42 (42.9%)

0.017

 In-field recurrence

7/54 (13.0%)

14/42 (33.3%)

0.017

 Out-field recurrence

4/54 (7.4%)

9/42 (21.4%)

0.046

Stage IIIC2

 Total recurrence

5/9 (55.6%)

10/15 (66.7%)

0.687

 In-field recurrence

4/9 (44.4%)

8/15 (53.3%)

1

 Out-field recurrence

2/9 (22.2%)

7/15 (46.7%)

0.389

Stage IVA

 Total recurrence

2/7(28.6%)

4/7 (57.1%)

0.592

 In-field recurrence

1/7 (14.3%)

2/7 (28.6%)

1

 Out-field recurrence

1/7(14.3%)

3/7(42.9%)

0.559